Supernus CEO awarded 341,610 stock options

SUPERNUS PHARMACEUTICALS, INC. reported that President and CEO Jack A. Khattar received a grant of employee stock options for 341,610 shares on February 18, 2026.

Accepted by SEC EDGAR 02/20/2026 - 04:46 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. reported that President and CEO Jack A. Khattar received a grant of employee stock options for 341,610 shares on February 18, 2026. The options were awarded as a grant/award acquisition and vest in four equal annual installments beginning on February 18, 2027.

Insider Trade Summary

Grant/Award: 341,610 shares

Grant/Award 1 txn

Insider Khattar Jack A.

Role President, CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	341,610	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 341,610 contracts (Direct)

Holdings Before and After: Employee Stock Option (Right to Buy), 0 to 341,610 contracts (Direct)

Footnotes (1)

1. F1. The option vests in four equal annual installments beginning on February 18, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SUPN report for Jack A. Khattar?

SUPN reported that President and CEO Jack A. Khattar received a grant of employee stock options for 341,610 shares. The award was recorded on February 18, 2026, as a grant or other acquisition rather than an open-market purchase or sale.

How many stock options were granted to the SUPN CEO in this Form 4?

The Form 4 shows a grant of employee stock options covering 341,610 shares for CEO Jack A. Khattar. These options are recorded as directly owned and increase his derivative holdings to a total of 341,610 option-based shares following the reported transaction.

When do Jack A. Khattar’s SUPN stock options begin vesting?

The options begin vesting on February 18, 2027. According to the disclosure footnote, they vest in four equal annual installments, meaning the grant becomes exercisable gradually over four years starting from that February 18, 2027 vesting date.

What is the vesting schedule for the SUPN CEO’s new stock options?

The employee stock options granted to Jack A. Khattar vest in four equal annual installments. The first installment vests on February 18, 2027, with additional equal portions vesting on each of the next three anniversaries of that initial vesting date.

Is the SUPN CEO’s Form 4 transaction a purchase or a grant?

The transaction is reported as a grant or award acquisition, not an open-market purchase. The Form 4 uses transaction code A and describes it as a grant, award, or other acquisition of employee stock options rather than a buy or sell of existing shares.

How is ownership of the new SUPN stock options classified?

Ownership of the new employee stock options is classified as direct. The filing notes the options as directly owned by Jack A. Khattar, with 341,610 derivative securities shown as the total number of options held following the completion of this reported grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khattar Jack A.

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS INC.

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$50.2	02/18/2026		A		341,610		(1)	02/18/2036	Common Stock	341,610	$0	341,610	D

Explanation of Responses:

1. The option vests in four equal annual installments beginning on February 18, 2027.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.